The 10th edition of AAM’s annual generic drug savings and access report, which was released last month, is full of important data for policymakers as well as industry leaders. The report provides detailed information on savings by state, payer type, treatment area, and other factors, as well as the state of the biosimilars market. Here are 10 noteworthy takeaways from the publication.
New report provides further evidence of patent abuse
WASHINGTON, DC (May 18, 2018) –AAM filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit calling on the court to reject gamesmanship of the patent system which keeps prescription drug prices high for patients. In this case, Allergan Inc. has transferred its patents to the St. Regis Mohawk Native American Tribe with the intent to use the tribe’s sovereign immunity to evade review of the drug company’s patents. AAM is joining with a diverse range of groups, including America’s Health Insurance Plans, in opposing this abuse of the patent system.
Administration’s Plan Embraces Getting More Generic and Biosimilar Medicines to Patients
WASHINGTON DC (May 11, 2018) – In President Trump’s remarks today at the White House, he made clear the essential role that generic and biosimilar medicines play in containing prescription drug costs for patients.
Biosimilars have the potential to improve quality of life for patients. If the right policies are put in place to cultivate a robust market, an additional 1.2 million patients will have access to biologic medicines, while also saving an estimated $54 billion over the next 10 years.
The bipartisan PACED Act would stop Allergan’s patent abuse
Brand pharmaceutical companies are finding new, innovative ways to avoid competition from generic and biosimilar medicines, extend their government-provided monopolies and keep patients paying high drug prices. Look no further than Allergan.
Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out of reach for far too many patients.
Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out of reach for far too many patients.
Share the infographic below to help educate lawmakers on how generic and biosimilar medicines are the remedy to high drug costs.
MEDIA ADVISORY